ARTICLE | Finance

Waiting for better times

Why Molecular Partners postponed the fourth-largest EU biotech IPO since 2008

October 27, 2014 7:00 AM UTC

Poised to complete the fourth-largest European biotech IPO since 2008, the road show for Molecular Partners AG had the poor luck of coinciding with the largest one-week drop in the broader capital markets since the start of 2013. Because it has plenty of cash, the protein scaffold play decided to postpone its listing on the SIX Swiss Exchange.

On Sept. 23, Molecular Partners filed to raise up to CHF125 million ($133.1 million) in an IPO on the exchange...